N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-N-[2-[(methylsulfonyl)oxy]ethyl]glycine 1,1-dimethylethyl ester | 871235-17-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-N-[2-[(methylsulfonyl)oxy]ethyl]glycine 1,1-dimethylethyl ester
• 英文别名: tert-butyl N-(tert-butoxycarbonylmethyl)-N-(2-methylsulfonyloxyethyl)aminoacetate；ethylene glycol tetraacetic acid
• CAS: 871235-17-5
• 化学式: C₁₅H₂₉NO₇S
• 分子量: 367.464
• InChiKey: WTYZNEOWIJEKPW-UHFFFAOYSA-N

物化性质

• 沸点：
  463.6±40.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.95
• 重原子数：
  24.0
• 可旋转键数：
  8.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  99.21
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-N-[2-[(methylsulfonyl)oxy]ethyl]glycine 1,1-dimethylethyl ester 在 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 5.0h， 生成 Methyl 6-[[2-[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethoxy]ethyl-[(6-methoxycarbonylpyridin-2-yl)methyl]amino]methyl]pyridine-2-carboxylate
  参考文献：
  名称：

  [EN] CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME
  [FR] CHÉLATEURS POUR RADIOMÉTAUX ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION

  摘要：

  提供具有一般结构（I）的螯合剂，其中每个R1独立地是OH，NH或SH，而X是O，S或NR3，其中R3为H或CH2C（= O）R1。提供制备和使用螯合剂，金属螯合物和生物构造物的方法，用于使用螯合剂提供靶向放射治疗。 (I)。

  公开号：

  WO2022232943A1
• 作为产物：
  描述：

  二(2-甲基-2-丙基)2,2'-[(2-羟基乙基)亚氨基]二乙酸酯 在 碳酸氢钠 、 三乙胺 作用下， 以 二氯甲烷 、 甲基磺酰氯 为溶剂， 以99%的产率得到N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-N-[2-[(methylsulfonyl)oxy]ethyl]glycine 1,1-dimethylethyl ester
  参考文献：
  名称：

  Pharmaceutical compositions comprising metal complexes

  摘要：

  该化合物的化学式为[Ma(XbL)cYdZe]nt±Formula I其中：M是金属离子或金属离子的混合物；X是阳离子或阳离子的混合物；L是配体，或者是至少含有周期表IV、V或VI族元素中至少两种不同供体原子的配体混合物；Y是配体或者是至少含有周期表IV、V或VI族元素中至少一个供体原子或多个供体原子的相同或不同配体的混合物；Z是卤素或伪卤素离子或卤素离子和伪卤素离子的混合物；并且其中：a=1-3；b=0-12；c=0-18；d=0-18；e=0-18；n=0-10；前提是c、d和e中至少有一个大于等于1；其中c为0时：b也为0；其中a为1时：c、d和e均不大于9；其中a为2时：c、d和e均不大于12。

  公开号：

  US20020049190A1

文献信息

• BIHETEROCYCLIC COMPOUND
  申请人：SUMITOMO DAINIPPON PHARMA CO., LTD.

  公开号：US20190016711A1

  公开（公告）日：2019-01-17

  The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R 1 -L- is R 1 —OC(O)—, or the like, R 1 is hydrogen atom, optionally-substituted C 1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R 2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R 3 is hydrogen atom, optionally-substituted C 1-6 alkyl group, or the like, the part of X, Y, and Z is X═Y—Z, X—Y═Z, or X—Y—Z, X is nitrogen atom, NR 4 (R 4 is hydrogen atom, optionally-substituted C 1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.

  本发明提供了一种具有式（1）的化合物和包括该化合物的药物组合物，其用作神经再生促进剂，其中R1-L-为R1—OC(O)—，或类似物，R1为氢原子，可选择取代的C1-6烷基基团，可选择取代的3-至8-成员环烷基基团，或类似物，R2为氢原子或类似物，环A为式（2）或式（3），其中R3为氢原子，可选择取代的C1-6烷基基团，或类似物，X、Y和Z的部分为X═Y—Z，X—Y═Z，或X—Y—Z，X为氮原子，NR4（R4为氢原子，可选择取代的C1-6烷基基团，或类似物），或类似物，Y为碳原子或类似物，Z为碳原子，氮原子或类似物。
• Synthesis and solution thermodynamic study of rigidified and functionalised EGTA derivatives
  作者：Lorenzo Tei、Zsolt Baranyai、Mauro Botta、Laura Piscopo、Silvio Aime、Giovanni B. Giovenzana

  DOI：10.1039/b804195d

  日期：——

  (ethyleneglycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid) derivatives incorporating aromatic and functionalized aromatic moieties into the oxoethylenic bridge is described. A solution thermodynamic study was carried out to determine the influence of structural modifications on the coordinating ability towards lanthanide and alkaline earth metal ions. The presence of remote functional groups

  描述了一系列新的EGTA（乙二醇-双（2-氨基乙基醚）-N，N，N'，N'-四乙酸）衍生物的合成，这些衍生物将芳族和官能化的芳族部分引入了氧乙烯烯桥中。进行了溶液热力学研究，以确定结构修饰对镧系元素和碱土金属离子配位能力的影响。芳族部分上远程官能团的存在将使复合物与大分子或其他生物靶标结合。
• Ru ^III Complexes of Edta and Dtpa Polyaminocarboxylate Analogues and Their Use as Nitric Oxide Scavengers
  作者：Tim Storr、Beth R. Cameron、Robert A. Gossage、Helen Yee、Renato T. Skerlj、Marilyn C. Darkes、Simon P. Fricker、Gary J. Bridger、Nathan A. Davies、Michael T. Wilson、Kevin P. Maresca、Jon Zubieta

  DOI：10.1002/ejic.200500018

  日期：2005.7

  also measured, indicating the tight binding of NO by the Ru I I I complexes. The activity of the Ru I I I complexes to scavenge nitric oxide was evaluated using RAW264 murine macrophage cells. Ligand analogues of edta that have a pyridine donor as part of the N,N chelate such as 20 and 24 exhibit similar scavenging activity to the parent compound. Ligand analogues of dtpa that have R groups at the central

  在这项研究中，生产了一系列由乙二胺四乙酸 (edta) 和二亚乙基三胺五乙酸 (dtpa) 的类似物螯合的 Ru III 配合物，并测试了 NO 清除能力。对 edta 和 dtpa 配体框架进行了修改，以改变所得 Ru III 配合物的反应性、水性稳定性和药代动力学。亚硝酰基配合物 38 的 X 射线结构证实 Ru III 配合物 27 与 NO 反应形成线性 Ru-NO} [ 6 ] 配合物。亚硝酰基络合物 [C 1 5 H 1 5 N 4 O 1 1 Ru] 在 P2 1 /c 空间群中结晶，a = 12.731(3) A, b = 10.894(2) A, c = 14.241 (3) A , β = 107.320(4)°, V = 1885.6(7)A 3 , and Z = 4. 14 (k = 2.38×10 6 M - 1 s - 1 )和27 (k = 2)反应的动力学研究
• Calcium depletion-mediated protease inhibition and apical-junctional-complex disassembly via an EGTA-conjugated carrier for oral insulin delivery
  作者：Er-Yuan Chuang、Kun-Ju Lin、Fang-Yi Su、Hsin-Lung Chen、Barnali Maiti、Yi-Cheng Ho、Tzu-Chen Yen、Nilendu Panda、Hsing-Wen Sung

  DOI：10.1016/j.jconrel.2012.11.011

  日期：2013.8

  Calcium (Ca2+) has a crucial role in maintaining the intestinal protease activity and in forming the apical junctional complex (AJC) that preserves epithelial barrier function. Ethylene glycol tetraacetic acid (EGTA) is a Ca2+-specific chelating agent. To maintain the concentration of this chelator in areas where enzyme inhibition and paracellular permeation enhancement are needed, this study synthesized a poly(gamma-glutamic acid)-EGTA conjugate (gamma PGA-EGTA) to form nanoparticles (NPs) with chitosan (CS) for oral insulin delivery. The results of our molecular dynamic (MD) simulations indicate that Ca2+ ions could be specifically chelated to the nitrogen atoms, ether oxygen atoms, and carboxylate oxygen atoms in [Ca(EGTA)](2-) anions. By chelating Ca2+, gamma PGA-EGTA conferred a significant insulin protection effect against proteases in intestinal tracts isolated from rats. Additionally, calcium depletion by gamma PGA-EGTA could stimulate the endocytosis of AJC components in Caco-2 cell monolayers, which led to a reversible opening of AJCs and thus increased their paracellular permeability. Single-photon emission computed tomography images performed in the biodistribution study clearly show the I-123-insulin orally delivered by CS/gamma PGA-EGTA NPs in the heart, aorta, renal cortex, renal pelvis and liver, which ultimately produced a significant and prolonged hypoglycemic effect in diabetic rats. The above results confirm that this gamma PGA-EGTA conjugate is a promising candidate for oral insulin delivery. (C) 2012 Elsevier B. V. All rights reserved.
• Scale-Up of Trisodium [(3β,5β,12α)-3-[[4(<i>S</i>)-4-[Bis[2-[bis[(carboxy-<i>kO</i>)methyl]amino-<i>kN</i>]ethyl]amino-<i>kN</i>]-4-(carboxy-<i>kO</i>)-1-oxobutyl]amino]-12-hydroxycholan-24-oato(6-)]gadolinate(3-)], a Gd(III) Complex under Development As a Contrast Agent for MRI Coronary Angiography
  作者：Pier Lucio Anelli、Marino Brocchetta、Luciano Lattuada、Giuseppe Manfredi、Pierfrancesco Morosini、Marcella Murru、Daniela Palano、Marco Sipioni、Massimo Visigalli

  DOI：10.1021/op900008a

  日期：2009.7.17

  Process chemistry involved in the discovery and development routes to trisodium [(3 beta,5 beta,12(alpha)-3-[[4(S)-4-[bis[2-[bis[(carboxy-kO)methyl]amino-kN]ethyl]amino-kN]4-(carboxy-kO)-1-oxobutyl]- amino]-12-hydroxycholan-24-oato(6-)]gadolinate(3-)] (B22956/1) starting from L-glutamic acid and (3 alpha,5 beta,12 alpha)-3,12-dihydroxycholan-24-oic acid is described. The best process is based on seven chemical steps and overcomes difficult purification protocols. Such process has been successfully implemented to prepare multikilogram batches of the target compound in 20% overall yield from (3 alpha,5 beta,12 alpha)-3,12-dihydroxycholan-24-oic acid.